Overview
Tucatinib is an oral, highly selective HER2-targeted tyrosine kinase inhibitor. It blocks HER2-mediated signalling pathways involved in cancer cell growth and proliferation. It is used in combination with other therapies for eligible patients with HER2-positive advanced or metastatic breast cancer.